Affordable Access

[Efficacy of tacrolimus for joint destruction in rheumatoid arthritis].

Authors
  • Tanaka, Yoshiya
  • Suzuki, Katsunori
  • Saito, Kazuyoshi
Type
Published Article
Journal
Clinical calcium
Publication Date
Apr 01, 2007
Volume
17
Issue
4
Pages
593–599
Identifiers
PMID: 17404490
Source
Medline
License
Unknown

Abstract

Since joint destruction, the most important problem in rheumatoid arthritis (RA) , progress rapidly at the onset of the disease, initial treatment using appropriate disease-modifying anti-rheumatic drug DMARD such as methotrexate (MTX) is strongly recommended in order to retard progression of joint damage. However, not a few patients are resistant to MTX and/or intolerant of MTX. Oral tacrolimus 1.5-3 mg/day, an immunosuppressive drug, was approved in Japan for the treatment of RA insufficient to other DMARD. The properties of tacrolimus have the much potential of inhibition of T cell activation, suppressing the production of pro-inflammatory cytokines, improvement of joint inflammation, retarding bone and cartilage destruction, overcoming drug-resistance and so on and, thereby, tacrolimus can be the best alternative to MTX and biologics in RA patients who are refractory to or intolerant of these other drugs.

Report this publication

Statistics

Seen <100 times